首页> 美国卫生研究院文献>Heliyon >Safety of oral administration of high doses of ivermectin by means of biocompatible polyelectrolytes formulation
【2h】

Safety of oral administration of high doses of ivermectin by means of biocompatible polyelectrolytes formulation

机译:通过生物相容性聚电解质制剂口服高剂量in invermectin的安全性

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The FDA-approved drug ivermectin is applied for treatments of onchocerciasis and lymphatic filariasis. The anti-cancer and anti-viral activities have been demonstrated stressing possibilities for the drug repurposing and therefore new information on high dosage safety is on demand. We analyzed in vivo tissue responses for high doses of ivermectin using Corydoras fish as animal model. We made intestinal histology and hematologic assays after oral administration of ivermectin transported with polyelectrolytes formulation. Histology showed any apparent damage of intestinal tissues at 0.22–170 mg of ivermectin/kg body weight. Immunofluorescence evidenced delocalization of Myosin-Vb at enterocytes only for the higher dose. Hematology parameters showed random variations after 7 days from administration, but a later apparent recover after 14 and 21 days. The study evaluated the potential of high doses of oral administration of ivermectin formulation, which could be an alternative with benefits in high compliance therapies.
机译:FDA批准的药物Ivermectin用于治疗onchocercivesis和淋巴丝虫病。已经证明了抗癌和抗病毒活性的强调药物重估的可能性,因此有关高剂量安全的新信息是根据需求的。我们使用Corydoras Fish作为动物模型对高剂量的伊维菌素进行体内组织反应进行分析。在用聚电解质制剂中运输的伊维菌素口服施用后,我们制造了肠道组织学和血液学测定。组织学表明肠组织的任何明显损伤在0.22-170mg的伊维菌素/ kg体重。免疫荧光在肠细胞中显现的肌蛋白-VB的删除性仅为较高剂量。血液学参数在给药后7天后显示随机变化,但在14和21天后后来明显恢复。该研究评估了伊维菌素制剂高剂量口服施用的潜力,这可能是高智能疗法中益处的替代品。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号